InvestorsHub Logo
Followers 44
Posts 2387
Boards Moderated 0
Alias Born 08/09/2016

Re: Whalatane post# 117197

Tuesday, 10/31/2017 10:19:39 AM

Tuesday, October 31, 2017 10:19:39 AM

Post# of 426389
Kiwi - I have been involved in drug patent challenges. I beleive that whether or not generic high purity EPA products violate the V patents depends on the wording AMRN used in the patents. The patents I have seen list a range of doses rather than a single dose (to cover themselves broadly). So, if the ARMN patents for V said "EPA between 80 - 100% pure, with less than 10% DHA", all high purity EPA currently sold as DS would violate the patents. I have not read the patents, so do not know if this is the case though.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News